Intercellular pathways of cancer treatment-related cardiotoxicity and their therapeutic implications: The paradigm of radiotherapy.

[1]  N. Wilcox,et al.  Cardiovascular disease and cancer: shared risk factors and mechanisms. , 2024, Nature reviews. Cardiology.

[2]  P. Roy,et al.  Breaking tolerance: the autoimmune aspect of atherosclerosis. , 2024, Nature reviews. Immunology.

[3]  A. Weeraratna,et al.  Embracing cancer complexity: Hallmarks of systemic disease , 2024, Cell.

[4]  S. Kussauer,et al.  Heart rhythm in vitro: measuring stem cell-derived pacemaker cells on microelectrode arrays , 2024, Frontiers in cardiovascular medicine.

[5]  M. Canepa,et al.  Ischaemic heart disease in patients with cancer. , 2024, European heart journal.

[6]  B. Koczwara,et al.  Integrating CardioOncology Across the Research Pipeline, Policy, and Practice in Australia-An Australian Cardiovascular Alliance Perspective. , 2024, Heart, lung & circulation.

[7]  Richard Von Itter,et al.  Cross-Disease Communication in Cardiovascular Disease and Cancer , 2024, JACC. CardioOncology.

[8]  Y. Takeishi,et al.  Heart Failure Post-Myocardial Infarction Promotes Mammary Tumor Growth Through the NGF-TRKA Pathway , 2023, JACC CardioOncology.

[9]  Hamid Khoshfekr Rudsari,et al.  Human Heart Organoid-derived Extracellular Vesicles for Cardiac Intercellular Communication , 2023, Annual International Conference on Nanoscale Computing and Communication.

[10]  M. Malik,et al.  Cardiotoxicity in breast cancer treatment: Causes and mitigation. , 2023, Cancer treatment and research communications.

[11]  W. Tong,et al.  Multi-omics data integration using ratio-based quantitative profiling with Quartet reference materials. , 2023, Nature biotechnology.

[12]  A. Ghigo,et al.  Priorities in Cardio-Oncology Basic and Translational Science , 2023, JACC. CardioOncology.

[13]  E. Lehrer,et al.  Combining Radiotherapy and Immunotherapy in Head and Neck Cancer , 2023, Biomedicines.

[14]  T. Neilan,et al.  Mediators and mechanisms of immune checkpoint inhibitor‐associated myocarditis: Insights from mouse and human , 2023, Immunological reviews.

[15]  Jiangnan Zheng,et al.  Deciphering intercellular signaling complexes by interaction-guided chemical proteomics , 2023, Nature communications.

[16]  Mariano I. Gabitto,et al.  MultiVI: deep generative model for the integration of multimodal data , 2023, Nature Methods.

[17]  N. Le.  Leveraging transformers‐based language models in proteome bioinformatics , 2023, Proteomics.

[18]  J. Saez-Rodriguez,et al.  Gene regulatory network inference in the era of single-cell multi-omics , 2023, Nature Reviews Genetics.

[19]  B. Ky,et al.  Risk of Cardiovascular Events Among Patients With Head and Neck Cancer. , 2023, JAMA otolaryngology-- head & neck surgery.

[20]  I. Balasingham,et al.  Modeling Extracellular Vesicles-Mediated Interactions of Cells in the Tumor Microenvironment , 2023, IEEE Transactions on NanoBioscience.

[21]  G. Armstrong,et al.  Cardiac Substructure Radiation Dose and Risk of Late Cardiac Disease in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Harmsen,et al.  Towards standardization of human adipose-derived stromal cells secretomes , 2023, Stem Cell Reviews and Reports.

[23]  A. DeMichele,et al.  Adverse Cardiovascular Events Associated With Cyclin‐Dependent Kinase 4/6 Inhibitors in Patients With Metastatic Breast Cancer , 2023, Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease.

[24]  C. N. Coleman,et al.  Emerging evidence for adapting radiotherapy to immunotherapy , 2023, Nature Reviews Clinical Oncology.

[25]  L. Thomas,et al.  When Cancer and Cardiovascular Disease Intersect: The Challenge and the Opportunity of Cardio-Oncology. , 2023, Heart, lung & circulation.

[26]  Ju Gao,et al.  Characteristics and research status among clinical trials in cardio‐oncology by bibliometric and visualized analysis , 2023, Cancer medicine.

[27]  L. Foster,et al.  Integration of data‐independent acquisition (DIA) with co‐fractionation mass spectrometry (CF‐MS) to enhance interactome mapping capabilities , 2023, Proteomics.

[28]  M. Mann,et al.  MS-Based Proteomics of Body Fluids: The End of the Beginning , 2023, Molecular & cellular proteomics : MCP.

[29]  M. Quirch,et al.  Nivolumab‐induced fatal myocarditis: A case report , 2023, Clinical case reports.

[30]  J. Witjes,et al.  Cardiovascular Disease in Testicular Cancer Survivors: Identification of Risk Factors and Impact on Quality of Life , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  Sahadev A Shankarappa,et al.  Secretome mediated interactions between sensory neurons and breast cancer cells , 2023, International journal of cancer.

[32]  D. Quail,et al.  Fueling the Tumor Microenvironment with Cancer-Associated Adipocytes. , 2023, Cancer research.

[33]  C. Magnon,et al.  The neural addiction of cancer , 2023, Nature Reviews Cancer.

[34]  D. Shin,et al.  Pembrolizumab and cabozantinib in recurrent metastatic head and neck squamous cell carcinoma: a phase 2 trial , 2023, Nature Medicine.

[35]  Hamid Khoshfekr Rudsari,et al.  Computational estimation of chemical reaction rates in extracellular vesicle signaling , 2023, Nano Commun. Networks.

[36]  Dae Hyun Lee,et al.  Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study , 2023, Cardio-Oncology.

[37]  T. Kuner,et al.  Cancer neuroscience: State of the field, emerging directions , 2023, Cell.

[38]  M. Scherrer-Crosbie,et al.  Cancer Treatment-Related Cardiovascular Toxicity in Gynecologic Malignancies , 2023, JACC. CardioOncology.

[39]  J. Bauman,et al.  Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Katsouras,et al.  Radiation Treatment Mechanisms of Cardiotoxicity: A Systematic Review , 2023, International journal of molecular sciences.

[41]  V. Bhatt,et al.  Cardiotoxicities of Novel Therapies in Hematologic Malignancies: Chimeric Antigen Receptor T-Cell Therapy and Bispecific T-Cell Engager Therapy. , 2023, JCO oncology practice.

[42]  A. Einstein,et al.  Ionising radiation and cardiovascular disease: systematic review and meta-analysis , 2023, BMJ.

[43]  T. Voet,et al.  Methods and applications for single-cell and spatial multi-omics , 2023, Nature Reviews Genetics.

[44]  A. Mosley,et al.  A human skeletal muscle stem/myotube model reveals multiple signaling targets of cancer secretome in skeletal muscle. , 2023, iScience.

[45]  Hamid Khoshfekr Rudsari,et al.  Anomalous Diffusion of Extracellular Vesicles in an Extracellular Matrix for Molecular Communication , 2023, IEEE Transactions on Molecular, Biological and Multi-Scale Communications.

[46]  G. Wang,et al.  Risk factors for fluoropyrimidine-induced cardiotoxicity in colorectal cancer: A retrospective cohort study and establishment of a prediction nomogram for 5-FU induced cardiotoxicity , 2023, Frontiers in Oncology.

[47]  L. Zheng,et al.  Cardiotoxicity from neoadjuvant targeted treatment for breast cancer prior to surgery , 2023, Frontiers in Cardiovascular Medicine.

[48]  S. S. Nunes,et al.  Modeling Heart Diseases on a Chip: Advantages and Future Opportunities , 2023, Circulation research.

[49]  J. Loscalzo,et al.  Multiomics Network Medicine Approaches to Precision Medicine and Therapeutics in Cardiovascular Diseases. , 2023, Arteriosclerosis, Thrombosis and Vascular Biology.

[50]  S. Mackay,et al.  Applying single‐cell highly multiplexed secretome proteomics to characterize immunotherapeutic products and predict clinical responses , 2023, Proteomics.

[51]  N. Hübner,et al.  Spatially resolved multiomics of human cardiac niches , 2023, bioRxiv.

[52]  S. Deshmukh,et al.  Short text topic modelling using local and global word-context semantic correlation , 2023, Multimedia Tools and Applications.

[53]  I. Trougakos,et al.  Cardiovascular Toxicity of Proteasome Inhibitors: Underlying Mechanisms and Management Strategies , 2023, JACC. CardioOncology.

[54]  N. Arivazhagan,et al.  Natural Language Processing Basics. , 2023, American Society of Nephrology. Clinical Journal.

[55]  Mohamed Hegazy,et al.  Diagnosis and Management of Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Children , 2023, Children.

[56]  Athanasia Pavlopoulou,et al.  A Counterintuitive Neutrophil-Mediated Pattern in COVID-19 Patients Revealed through Transcriptomics Analysis , 2022, Viruses.

[57]  Satarupa Banerjee,et al.  Cancer secretome: finding out hidden messages in extracellular secretions , 2022, Clinical and Translational Oncology.

[58]  S. Gill,et al.  Cancer Immunotherapy Beyond Checkpoint Blockade , 2022, JACC. CardioOncology.

[59]  D. Day,et al.  Immune Checkpoint Inhibitor Therapy in Oncology , 2022, JACC. CardioOncology.

[60]  Hongbing Shen,et al.  Multi-omics profiling visualizes dynamics of cardiac development and functions. , 2022, Cell reports.

[61]  S. Mallal,et al.  T cells specific for α-myosin drive immunotherapy-related myocarditis , 2022, Nature.

[62]  Fiona M. I. Hunter,et al.  Multi-omics HeCaToS dataset of repeated dose toxicity for cardiotoxic & hepatotoxic compounds , 2022, Scientific Data.

[63]  Simmie L. Foster,et al.  Nociceptor neurons affect cancer immunosurveillance , 2022, Nature.

[64]  Athanasia Pavlopoulou,et al.  Radiation Type- and Dose-Specific Transcriptional Responses across Healthy and Diseased Mammalian Tissues , 2022, Antioxidants.

[65]  A. Cohen-Solal,et al.  European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment , 2022, European Heart Journal - Quality of Care and Clinical Outcomes.

[66]  James W. Clancy,et al.  Tumor-Derived Extracellular Vesicles: Multifunctional Entities in the Tumor Microenvironment , 2022, Annual review of pathology.

[67]  G. Boriani,et al.  2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). , 2022, European heart journal.

[68]  Stephan Marquardt,et al.  p73 isoforms meet evolution of metastasis. , 2022, Cancer metastasis reviews.

[69]  S. Giordano,et al.  Risk of Cancer After Diagnosis of Cardiovascular Disease , 2022, medRxiv.

[70]  E. Lengyel,et al.  The adipocyte microenvironment and cancer , 2022, Cancer and Metastasis Reviews.

[71]  C. Bouchard,et al.  Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods , 2022, Science advances.

[72]  Prof. Marcel Van Herk,et al.  SPATIAL GENE EXPRESSION CHANGES IN THE MOUSE HEART FOLLOWING BASE-TARGETED IRRADIATION. , 2022, International journal of radiation oncology, biology, physics.

[73]  G. Dittmar,et al.  Targeted proteomics on its way to discovery , 2022, Proteomics.

[74]  L. Hong,et al.  Arteriovenous thrombotic events in a patient with advanced lung cancer following bevacizumab plus chemotherapy: A case report , 2022, World journal of clinical cases.

[75]  Hamid Khoshfekr Rudsari,et al.  The End-to-End Molecular Communication Model of Extracellular Vesicle-Based Drug Delivery , 2022, IEEE Transactions on NanoBioscience.

[76]  N. Benkirane-Jessel,et al.  Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine , 2022, Biomedicines.

[77]  L. Minasian,et al.  Spectrum of National Institutes of Health-Funded Research in Cardio-Oncology: A Basic, Clinical, and Observational Science Perspective. , 2022, Heart failure clinics.

[78]  M. Totzeck,et al.  PD1 Deficiency Modifies Cardiac Immunity during Baseline Conditions and in Reperfused Acute Myocardial Infarction , 2022, International journal of molecular sciences.

[79]  A. Maity,et al.  Shining a FLASHlight on ultrahigh dose rate radiation and possible late toxicity. , 2022, Clinical Cancer Research.

[80]  R. Hubbard,et al.  Association Between Up-front Surgery and Risk of Stroke in US Veterans With Oropharyngeal Carcinoma. , 2022, JAMA otolaryngology-- head & neck surgery.

[81]  S. Epelman,et al.  A cardioimmunologist’s toolkit: genetic tools to dissect immune cells in cardiac disease , 2022, Nature Reviews Cardiology.

[82]  C. Iribarren,et al.  Risk of Cardiovascular Disease in Women With and Without Breast Cancer: The Pathways Heart Study , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  M. Galsky,et al.  Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors , 2022, Nature Communications.

[84]  Y. Yoon,et al.  From engineered heart tissue to cardiac organoid , 2022, Theranostics.

[85]  A. Clayton,et al.  Challenges and directions in studying cell–cell communication by extracellular vesicles , 2022, Nature Reviews Molecular Cell Biology.

[86]  Guiyu Wang,et al.  Association Between Radiotherapy and Death From Cardiovascular Disease Among Patients With Cancer: A Large Population‐Based Cohort Study , 2022, Journal of the American Heart Association.

[87]  T. Omland,et al.  The Role of Cardioprotection in Cancer Therapy Cardiotoxicity , 2022, JACC. CardioOncology.

[88]  Yun Yi Tan,et al.  Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors , 2022, JACC. CardioOncology.

[89]  M. Tonelli,et al.  Incident Cardiovascular Disease Among Adults With Cancer , 2022, JACC. CardioOncology.

[90]  O. Wolkenhauer,et al.  Monitoring the maturation of the sarcomere network: a super-resolution microscopy-based approach , 2022, Cellular and Molecular Life Sciences.

[91]  Steven H. Lin,et al.  Radiation-Induced Cardiovascular Disease: Mechanisms, Prevention, and Treatment , 2022, Current Oncology Reports.

[92]  L. Zitvogel,et al.  Immunogenic cell stress and death , 2022, Nature Immunology.

[93]  Eugenia Voytik,et al.  A practical guide to interpreting and generating bottom‐up proteomics data visualizations , 2022, Proteomics.

[94]  G. Chrousos,et al.  Thrombocytopenia in COVID-19 and vaccine-induced thrombotic thrombocytopenia , 2022, International journal of molecular medicine.

[95]  Melody Di Bona,et al.  Innate immune signaling drives late cardiac toxicity following DNA-damaging cancer therapies , 2021, bioRxiv.

[96]  T. Imamura,et al.  Acute Heart Failure in a Patient with Occult Barlow’s Disease Receiving Bevacizumab , 2021, Medicina.

[97]  M. Eisenberg,et al.  Radiation‐Induced Cardiovascular Disease: Review of an Underrecognized Pathology , 2021, Journal of the American Heart Association.

[98]  M. Ferencik,et al.  Cardiovascular Manifestations From Therapeutic Radiation , 2021, JACC. CardioOncology.

[99]  A. Hoeflich,et al.  Quality control in scRNA-Seq can discriminate pacemaker cells: the mtRNA bias , 2021, Cellular and Molecular Life Sciences.

[100]  T. Illidge,et al.  Immunomodulation by radiotherapy in tumour control and normal tissue toxicity , 2021, Nature Reviews Immunology.

[101]  P. Kharchenko.  The triumphs and limitations of computational methods for scRNA-seq , 2021, Nature Methods.

[102]  J. Martín,et al.  Cardiotoxicity of Radiation Therapy: Mechanisms, Management, and Mitigation , 2021, Current Treatment Options in Oncology.

[103]  Seil Oh,et al.  Risk of Atrial Fibrillation According to Cancer Type , 2021, JACC. CardioOncology.

[104]  Z. Ouyang,et al.  Single-cell lipidomics with high structural specificity by mass spectrometry , 2021, Nature Communications.

[105]  P. Libby,et al.  IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial , 2021, The Lancet.

[106]  Kathleen W. Zhang,et al.  Heart Failure With Targeted Cancer Therapies , 2021, Circulation research.

[107]  Douglas B. Johnson,et al.  Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies , 2021, Circulation research.

[108]  R. D. de Boer,et al.  Preclinical Models of Cancer Therapy-Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. , 2021, Circulation research.

[109]  M. Spitzer,et al.  Systemic immunity in cancer , 2021, Nature Reviews Cancer.

[110]  J. Dulak,et al.  Human-induced pluripotent stem cell-derived cardiomyocytes, 3D cardiac structures, and heart-on-a-chip as tools for drug research , 2021, Pflügers Archiv - European Journal of Physiology.

[111]  Kyungdo Han,et al.  The incidence of myocardial infarction and stroke in head and neck cancer patients , 2021, Scientific Reports.

[112]  Ravi B. Parikh,et al.  Assessment and Management of Cardiovascular Risk Factors Among US Veterans With Prostate Cancer , 2021, JAMA network open.

[113]  O. Wolkenhauer,et al.  Automated annotation of rare-cell types from single-cell RNA-sequencing data through synthetic oversampling , 2021, BMC Bioinformatics.

[114]  Trisha M. Westerhof,et al.  Engineered Tools to Study Intercellular Communication , 2020, Advanced science.

[115]  M. Mayr,et al.  Systems biology in cardiovascular disease: a multiomics approach , 2020, Nature Reviews Cardiology.

[116]  Pramod K. Guru,et al.  Atezolizumab-induced myositis and myocarditis in a patient with metastatic urothelial carcinoma , 2020, BMJ Case Reports.

[117]  T. Stiewe,et al.  Extracellular Vesicles: Messengers of p53 in Tumor–Stroma Communication and Cancer Metastasis , 2020, International journal of molecular sciences.

[118]  D. Hausenloy,et al.  Intercellular Communication in the Heart: Therapeutic Opportunities for Cardiac Ischemia. , 2020, Trends in molecular medicine.

[119]  Xiao-Fan Wang,et al.  Resident memory T cells in tumor-distant tissues fortify against metastasis formation , 2020, Cell reports.

[120]  P. Ponikowski,et al.  Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) , 2020, European journal of heart failure.

[121]  Fiona M. I. Hunter,et al.  Network integration and modelling of dynamic drug responses at multi-omics levels , 2020, Communications Biology.

[122]  Catherine L. Worth,et al.  Cells of the adult human heart , 2020, Nature.

[123]  H. Grotenhuis,et al.  Cardiac Disease in Childhood Cancer Survivors , 2020, JACC. CardioOncology.

[124]  Buzhou Tang,et al.  Health Natural Language Processing: Methodology Development and Applications , 2020, JMIR medical informatics.

[125]  K. Moore,et al.  Crosstalk Between the Heart and Cancer: Beyond Drug Toxicity. , 2020, Circulation.

[126]  J. Holfeld,et al.  Cardiotoxic mechanisms of cancer immunotherapy - A systematic review. , 2020, International journal of cardiology.

[127]  F. Barbé-Tuana,et al.  The interplay between immunosenescence and age-related diseases , 2020, Seminars in Immunopathology.

[128]  C. Robert.  A decade of immune-checkpoint inhibitors in cancer therapy , 2020, Nature Communications.

[129]  Z. Nahleh,et al.  Practical and cost-effective model to build and sustain a cardio-oncology program , 2020, Cardio-Oncology.

[130]  K. Moore,et al.  Myocardial infarction accelerates breast cancer via innate immune reprogramming , 2020, Nature Medicine.

[131]  M. Ashrafizadeh,et al.  Damage-associated molecular patterns in tumor radiotherapy. , 2020, International immunopharmacology.

[132]  E. Hirsch,et al.  Mechanisms underlying the cross‐talk between heart and cancer , 2020, The Journal of physiology.

[133]  N. Magné,et al.  Radiation-induced bystander and abscopal effects: important lessons from preclinical models , 2020, British Journal of Cancer.

[134]  Afshin Samali,et al.  Tumour Cell Secretome in Chemoresistance and Tumour Recurrence. , 2020, Trends in cancer.

[135]  R. Shofti,et al.  Early Cardiac Remodeling Promotes Tumor Growth and Metastasis , 2020, Circulation.

[136]  Nicholas G Zaorsky,et al.  Fatal heart disease among cancer patients , 2020, Nature Communications.

[137]  J. Herrmann.  Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia , 2020, Nature Reviews Cardiology.

[138]  J. Herrmann.  Vascular toxic effects of cancer therapies , 2020, Nature Reviews Cardiology.

[139]  Anne R. Pariser,et al.  Recent Advances in Systems and Network Medicine: Meeting Report from the First International Conference in Systems and Network Medicine , 2020, Systems medicine.

[140]  Dae Hyun Lee,et al.  Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge , 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[141]  S. Marchianò,et al.  Cardiomyocyte maturation: advances in knowledge and implications for regenerative medicine , 2020, Nature Reviews Cardiology.

[142]  T. Stiewe,et al.  p53’s Extended Reach: The Mutant p53 Secretome , 2020, Biomolecules.

[143]  Thea D. Tlsty,et al.  A framework for advancing our understanding of cancer-associated fibroblasts , 2020, Nature Reviews Cancer.

[144]  R. D. de Boer,et al.  Reverse Cardio‐Oncology: Cancer Development in Patients With Cardiovascular Disease , 2020, Journal of the American Heart Association.

[145]  Zenun Kastrati,et al.  WET: Word embedding-topic distribution vectors for MOOC video lectures dataset , 2020, Data in brief.

[146]  L. Galluzzi,et al.  Immunological impact of cell death signaling driven by radiation on the tumor microenvironment , 2019, Nature Immunology.

[147]  Lei Deng,et al.  A population-based study of cardiovascular disease mortality risk in US cancer patients. , 2019, European heart journal.

[148]  V. Espeli,et al.  Immunotherapies and Future Combination Strategies for Head and Neck Squamous Cell Carcinoma , 2019, International journal of molecular sciences.

[149]  Deepak L. Bhatt,et al.  Cardiovascular Toxicities of Immune Checkpoint Inhibitors: JACC Review Topic of the Week. , 2019, Journal of the American College of Cardiology.

[150]  B. Pützer,et al.  STAT3 and STAT5 Targeting for Simultaneous Management of Melanoma and Autoimmune Diseases , 2019, Cancers.

[151]  R. Zhou,et al.  DAMP-sensing receptors in sterile inflammation and inflammatory diseases , 2019, Nature Reviews Immunology.

[152]  K. Bhaskaran,et al.  Medium and long-term risks of specific cardiovascular diseases in survivors of 20 adult cancers: a population-based cohort study using multiple linked UK electronic health records databases , 2019, The Lancet.

[153]  Y. Xin,et al.  Radiation-induced heart disease: a review of classification, mechanism and prevention , 2019, International journal of biological sciences.

[154]  D. Schadendorf,et al.  Cardiovascular Adverse Events Associated With BRAF and MEK Inhibitors , 2019, JAMA network open.

[155]  Yohei Fujishima,et al.  Radiation-Induced Bystander Effect is Mediated by Mitochondrial DNA in Exosome-Like Vesicles , 2019, Scientific Reports.

[156]  Shikai Wu,et al.  Incidence of and risk factors for cardiotoxicity after fluorouracil-based chemotherapy in locally advanced or metastatic gastric cancer patients , 2019, Cancer Chemotherapy and Pharmacology.

[157]  A. Michael,et al.  Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK , 2019, British Journal of Cancer.

[158]  Y. Arbel,et al.  Cardio-toxicity among patients with sarcoma: a cardio-oncology registry , 2019, BMC Cancer.

[159]  G. Kristiansen,et al.  Long Term Remission and Cardiac Toxicity of a Combination of Ipilimumab and Nivolumab in a Patient With Metastatic Head and Neck Carcinoma After Progression Following Nivolumab Monotherapy , 2019, Front. Oncol..

[160]  E. Biskup,et al.  Anthracycline-induced cardiotoxicity in the chemotherapy treatment of breast cancer: Preventive strategies and treatment , 2019, Molecular and clinical oncology.

[161]  C. Perna,et al.  Cardiac toxicity of immune-checkpoint inhibitors: a clinical case of nivolumab-induced myocarditis and review of the evidence and new challenges , 2019, Cancer management and research.

[162]  G. Keller,et al.  Ibrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes , 2019, Stem cell reports.

[163]  K. Fujiwara,et al.  Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need. , 2019, Cardiovascular research.

[164]  A. Stevenson,et al.  A Functional Immune System Is Required for the Systemic Genotoxic Effects of Localized Irradiation. , 2019, International journal of radiation oncology, biology, physics.

[165]  Arjun K. Ghosh,et al.  Coronary Artery Vasospasm Induced by 5-fluorouracil: Proposed Mechanisms, Existing Management Options and Future Directions , 2019, Interventional cardiology.

[166]  Daniel King,et al.  ScispaCy: Fast and Robust Models for Biomedical Natural Language Processing , 2019, BioNLP@ACL.

[167]  A. Lichtman,et al.  T cell checkpoint regulators in the heart , 2019, Cardiovascular research.

[168]  Marc P. Bonaca,et al.  Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. , 2018, The Lancet. Oncology.

[169]  C. Stefanadis,et al.  Metastatic malignancies and the effect on arterial stiffness and blood pressure levels: the possible role of chemotherapy , 2018, OncoTargets and therapy.

[170]  M. Nahrendorf,et al.  Cardioimmunology: the immune system in cardiac homeostasis and disease , 2018, Nature Reviews Immunology.

[171]  Lyanne M. Kieneker,et al.  Heart Failure Stimulates Tumor Growth by Circulating Factors , 2018, Circulation.

[172]  Surbhi,et al.  A Role for Hypocretin/Orexin in Metabolic and Sleep Abnormalities in a Mouse Model of Non-metastatic Breast Cancer. , 2018, Cell metabolism.

[173]  A. Grothey,et al.  5-fluorouracil and cardiotoxicity: a review , 2018, Therapeutic advances in medical oncology.

[174]  M. Najafi,et al.  Intercellular communications-redox interactions in radiation toxicity; potential targets for radiation mitigation , 2018, Journal of Cell Communication and Signaling.

[175]  A. Hardikar,et al.  Recurrent Pericardial Effusion While Receiving Nivolumab for Metastatic Lung Adenocarcinoma: Case Report and Review of the Literature , 2018, Clinical lung cancer.

[176]  A. Cohen-Solal,et al.  Cancer diagnosis in patients with heart failure: epidemiology, clinical implications and gaps in knowledge , 2018, European journal of heart failure.

[177]  R. Sullivan,et al.  Myocarditis in Patients Treated With Immune Checkpoint Inhibitors. , 2018, Journal of the American College of Cardiology.

[178]  Bénédicte Lebrun-Vignes,et al.  Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis , 2018, The Lancet.

[179]  M. Najafi,et al.  Mechanisms of inflammatory responses to radiation and normal tissues toxicity: clinical implications , 2018, International journal of radiation biology.

[180]  Ingo Roeder,et al.  Whither systems medicine? , 2018, Experimental & Molecular Medicine.

[181]  S. Caja,et al.  Exosome-Based Cell-Cell Communication in the Tumor Microenvironment , 2018, Front. Cell Dev. Biol..

[182]  C. Barker,et al.  Cytokine release syndrome after radiation therapy: case report and review of the literature , 2018, Journal of Immunotherapy for Cancer.

[183]  G. Tortora,et al.  The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer , 2017, Clinical genitourinary cancer.

[184]  L. Galluzzi,et al.  Immune recognition of irradiated cancer cells , 2017, Immunological reviews.

[185]  R. Webb,et al.  Out of the frying pan and into the fire: damage-associated molecular patterns and cardiovascular toxicity following cancer therapy , 2017, Therapeutic advances in cardiovascular disease.

[186]  Abhishek Pandey,et al.  Natural language processing systems for capturing and standardizing unstructured clinical information: A systematic review , 2017, J. Biomed. Informatics.

[187]  P. Libby,et al.  Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease , 2017, The New England journal of medicine.

[188]  P. Rose,et al.  Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer. , 2017, Anti-cancer drugs.

[189]  R. Kitsis,et al.  Grounding Cardio-Oncology in Basic and Clinical Science. , 2017, Circulation.

[190]  F. Gosetti,et al.  Proteomic approaches to decipher cancer cell secretome. , 2017, Seminars in cell & developmental biology.

[191]  Wei Zhao,et al.  Atrial fibrillation was changed into sinus bradycardia in a ROS1-positive advanced lung adenocarcinoma patient who achieved durable response to Crizotinib , 2017, Medicine.

[192]  T. Münzel,et al.  New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma , 2017, Melanoma research.

[193]  Thomas R. Cox,et al.  Pre-metastatic niches: organ-specific homes for metastases , 2017, Nature Reviews Cancer.

[194]  Chao Cheng,et al.  Systematic Pan-Cancer Analysis Reveals Immune Cell Interactions in the Tumor Microenvironment. , 2017, Cancer research.

[195]  A. Kamel,et al.  Risk stratification and pattern of cardiotoxicity in pediatric Ewing sarcoma. , 2017, Journal of the Egyptian National Cancer Institute.

[196]  P. Burridge,et al.  Validating the pharmacogenomics of chemotherapy-induced cardiotoxicity: What is missing? , 2016, Pharmacology & therapeutics.

[197]  J. D. de Groot,et al.  Tolerability of Capecitabine Monotherapy in Metastatic Colorectal Cancer: A Real-World Study , 2016, Drugs in R&D.

[198]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[199]  K. Peter,et al.  Toll‐Like Receptor (TLR)4 and MyD88 are Essential for Atheroprotection by Peritoneal B1a B Cells , 2016, Journal of the American Heart Association.

[200]  S. Hall,et al.  Stroke After Radiation Therapy for Head and Neck Cancer: What Is the Risk? , 2016, International journal of radiation oncology, biology, physics.

[201]  Hussein Tawbi,et al.  Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy , 2016, Journal of Immunotherapy for Cancer.

[202]  R. Stewart,et al.  Systemic mechanisms and effects of ionizing radiation: A new 'old' paradigm of how the bystanders and distant can become the players. , 2016, Seminars in cancer biology.

[203]  Russ B Altman,et al.  Human induced pluripotent stem cell–derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity , 2016, Nature Medicine.

[204]  N. Mohan,et al.  Trastuzumab, but Not Pertuzumab, Dysregulates HER2 Signaling to Mediate Inhibition of Autophagy and Increase in Reactive Oxygen Species Production in Human Cardiomyocytes , 2016, Molecular Cancer Therapeutics.

[205]  A. Blaes,et al.  Shared Risk Factors in Cardiovascular Disease and Cancer , 2016, Circulation.

[206]  E. Negri,et al.  Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer , 2016, Internal and Emergency Medicine.

[207]  M. Mongillo,et al.  Intercellular communication lessons in heart failure , 2015, European journal of heart failure.

[208]  B. Baban,et al.  Circulating mitochondrial DNA and Toll-like receptor 9 are associated with vascular dysfunction in spontaneously hypertensive rats. , 2015, Cardiovascular research.

[209]  J. Raemaekers,et al.  Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk. , 2015, JAMA internal medicine.

[210]  J. Kostis,et al.  Radiation-Induced Heart Disease: Pathologic Abnormalities and Putative Mechanisms , 2015, Front. Oncol..

[211]  Stephen L. Brown,et al.  Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials , 2014, Radiation oncology journal.

[212]  B. Ky,et al.  Cancer Therapy–Induced Cardiotoxicity: Basic Mechanisms and Potential Cardioprotective Therapies , 2014, Journal of the American Heart Association.

[213]  Z. Tu,et al.  Similarity network fusion for aggregating data types on a genomic scale , 2014, Nature Methods.

[214]  Giuseppe Schettino,et al.  A Kinetic-Based Model of Radiation-Induced Intercellular Signalling , 2013, PloS one.

[215]  Conor K McGarry,et al.  A computational model of cellular response to modulated radiation fields. , 2012, International journal of radiation oncology, biology, physics.

[216]  L. Leinwand,et al.  Molecular and Cellular Pathobiology Cancer Causes Cardiac Atrophy and Autophagy in a Sexually Dimorphic Manner , 2011 .

[217]  H. Isoniemi,et al.  Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy , 2011, British Journal of Cancer.

[218]  J. Bartek,et al.  Long-distance inflammatory and genotoxic impact of cancer in vivo , 2010, Proceedings of the National Academy of Sciences.

[219]  A. Nakamura,et al.  Tumors induce complex DNA damage in distant proliferative tissues in vivo , 2010, Proceedings of the National Academy of Sciences.

[220]  Z. Werb,et al.  Tumors as organs: complex tissues that interface with the entire organism. , 2010, Developmental cell.

[221]  S. De Flora,et al.  Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention , 2010, Journal of the National Cancer Institute.

[222]  A. Lusis,et al.  Cardiovascular networks: systems-based approaches to cardiovascular disease. , 2010, Circulation.

[223]  M. Saif,et al.  Fluoropyrimidine-associated cardiotoxicity: revisited , 2009 .

[224]  H. M. Byrne,et al.  Mathematical Model for Low Density Lipoprotein (LDL) Endocytosis by Hepatocytes , 2008, Bulletin of mathematical biology.

[225]  S. Felix,et al.  Toll‐like receptor‐4 deficiency attenuates doxorubicin‐induced cardiomyopathy in mice , 2008, European journal of heart failure.

[226]  J. Forbes,et al.  Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[227]  D. Kerr,et al.  Rofecoxib and cardiovascular adverse events in adjuvant treatment of colorectal cancer. , 2007, The New England journal of medicine.

[228]  S. Yamada,et al.  High‐mobility group box 1 protein promotes development of microvascular thrombosis in rats , 2007, Journal of thrombosis and haemostasis : JTH.

[229]  Patrick F. Smith,et al.  Gemcitabine and Acute Myocardial Infarction , 2006, Angiology.

[230]  D. Ferrari,et al.  Gemcitabine and atrial fibrillation: a rare manifestation of chemotherapy toxicity. , 2006, Anti-cancer drugs.

[231]  T. Giordano,et al.  Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. , 2005, Cancer cell.

[232]  I. Kubota,et al.  Modulation of Doxorubicin-Induced Cardiac Dysfunction in Toll-Like Receptor-2–Knockout Mice , 2004, Circulation.

[233]  Michael S Ewer,et al.  Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. , 2004, Circulation.

[234]  A. Husain,et al.  Case Report and Brief Review: IL-2 Induced Myocarditis , 2004, Cancer investigation.

[235]  J. Bacri,et al.  Interaction of Anionic Superparamagnetic Nanoparticles with Cells: Kinetic Analyses of Membrane Adsorption and Subsequent Internalization , 2002 .

[236]  L. Moscetti,et al.  [Atrial fibrillation in a patient with non-small-cell carcinoma of the lung in the course of paclitaxel therapy]. , 1998, Clinica Terapeutica.

[237]  M. Citron,et al.  Dihydro‐5‐azacytidine in malignant mesothelioma , 1997, Cancer.

[238]  B. Jeremic,et al.  Cardiotoxicity during chemotherapy treatment with 5-fluorouracil and cisplatin. , 1990, Journal of chemotherapy.

[239]  OUP accepted manuscript , 2022, European Heart Journal.

[240]  N. Mackman,et al.  ATVB IN FOCUS: Cardiovascular Effects of Anticancer Treatments/Agents , 2021 .

[241]  Ho Kim,et al.  Radiotherapy can increase the risk of ischemic cerebrovascular disease in head and neck cancer patients: A Korean population-based cohort study. , 2019, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[242]  E. Fisher,et al.  Inflammatory processes in cardiovascular disease: a route to targeted therapies , 2017, Nature Reviews Cardiology.

[243]  H. Forrester,et al.  Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects. , 2015, Cancer letters.

[244]  C. Hudis,et al.  Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer , 2014, Breast Cancer Research and Treatment.

[245]  N. Gulbahce,et al.  Network medicine: a network-based approach to human disease , 2010, Nature Reviews Genetics.